Sera Prognostics
SERASera Prognostics is a women’s health company that leverages a proprietary proteomics and bioinformatics platform to improve maternal and neonatal outcomes.
Earnings
Next report
Nov 12, 2026 (in a month)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Sera Prognostics is a women’s health company that leverages a proprietary proteomics and bioinformatics platform to improve maternal and neonatal outcomes. The company develops and commercializes non-invasive, blood-based biomarker tests designed to provide early, actionable information regarding pregnancy complications. Its core value proposition focuses on identifying high-risk pregnancies to enable personalized interventions that reduce neonatal morbidity and healthcare costs.
The company is a pioneer in proteomic-based preterm birth risk assessment, offering the only broadly validated, commercially available blood test for this specific clinical application.
FAQ
- What is Sera Prognostics's market cap?
- Sera Prognostics (SERA) has a market capitalization of $79.7M and trades on NASDAQ.
- What is Sera Prognostics's revenue and profitability?
- Sera Prognostics generated $70.0K in trailing twelve-month revenue with a net loss of $33.2M, representing a net margin of -47475.7%, with free cash flow of -$28.1M. The latest reported period is Q2 2026.
- Who are Sera Prognostics's competitors?
- Sera Prognostics's key competitors include Natera, Myriad Genetics, Labcorp, and others. These companies compete in similar markets and product categories.
- Who does Sera Prognostics partner with?
- Sera Prognostics's notable partners include American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine, March of Dimes.
- Where is Sera Prognostics headquartered?
- Sera Prognostics is headquartered in United States of America and employs approximately 57 people. It has been publicly traded since 2021.
